NAD+ and Cellular Aging: What the Research Actually Says

NAD+ occupies an unusual position in longevity science. The underlying biology is not fringe — it's textbook biochemistry, worked out across decades, and the age-related decline is a real, replicated observation. Serious laboratories at Harvard, Washington University, and elsewhere have spent years on it.

And the human clinical results have been, so far, considerably more modest than the enthusiasm around them.

Both of those statements are true at once, and holding both is the only defensible position right now. This article walks through what's established, what's suggestive, and what's being sold well ahead of the evidence.

What NAD+ is

Nicotinamide adenine dinucleotide is a coenzyme present in every cell you have. It does two distinct jobs, and the distinction turns out to matter enormously.

Job one: moving electrons. NAD+ is the primary electron carrier in energy metabolism. Glycolysis, the citric acid cycle, fatty acid oxidation — all of it depends on NAD+ accepting electrons (becoming NADH) and then handing them to the electron transport chain to produce ATP. In this role NAD+ is recycled, not consumed. It flips back and forth between NAD+ and NADH millions of times.

Job two: being used up. A separate set of enzymes consumes NAD+ as a substrate, cleaving it and destroying the molecule in the process. Three families matter:

• Sirtuins (SIRT1–7) remove acetyl groups from proteins, influencing mitochondrial biogenesis, DNA repair, circadian rhythm, and inflammatory signaling. They are entirely NAD+-dependent — no NAD+, no sirtuin activity.
• PARPs detect and repair DNA damage. Each repair event consumes NAD+. Accumulating DNA damage means accumulating NAD+ drain.
• CD38, an enzyme on immune cells, is a voracious NAD+ consumer. Its expression rises substantially with age, driven in part by chronic low-grade inflammation.

So NAD+ sits at the intersection of energy production, DNA repair, and the regulatory machinery that governs how cells age. That is why it attracted the attention it did. It isn't a vitamin someone decided to market — it's a genuine hub.

The decline, and what drives it

NAD+ levels fall with age. This has been measured in human skin, liver, muscle, brain, and plasma, across multiple research groups. Estimates of magnitude vary widely by tissue and by measurement method — figures from 10% to 50% or more across adulthood appear in the literature, and the imprecision is real. But the direction is consistent.

The interesting question is why, because two mechanisms are possible and they imply different solutions.

Reduced production. The salvage pathway — which recycles nicotinamide back into NAD+ via the rate-limiting enzyme NAMPT — becomes less efficient with age. Less NAMPT, less regeneration.

Increased consumption. CD38 expression climbs with age. PARP activity climbs as DNA damage accumulates. The molecule is being destroyed faster.

Current evidence suggests both contribute, with rising consumption looking like the larger factor. This matters practically: if the dominant problem is a leaking bucket rather than a slow tap, adding water may not be the most efficient fix. Some researchers argue that inhibiting CD38 could be more effective than supplying precursors. That work is early.

There's also a chicken-and-egg problem the field hasn't resolved. Falling NAD+ might drive aging. Or it might be a consequence of it — the downstream result of inflammation and DNA damage that are themselves the primary drivers. If it's the latter, raising NAD+ treats a readout rather than a cause. Nobody knows yet, and this uncertainty sits underneath everything below.

Why you can't just take NAD+

Straightforward idea: levels are low, so swallow NAD+. It doesn't work that way.

NAD+ is a large, charged molecule. It doesn't readily cross cell membranes. Taken orally, it's broken down in the gut before absorption. Even delivered intravenously, it's largely degraded in the bloodstream by extracellular enzymes into smaller pieces — nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and nicotinamide (NAM) — which are then taken up by cells and rebuilt into NAD+ internally.

Which means the practical route is precursors:

• Nicotinamide riboside (NR) — the most studied in humans, with the largest body of published trial data.
• Nicotinamide mononucleotide (NMN) — one step further along the pathway. Its supplement status was in limbo from 2022, when the FDA said it was excluded because it had been investigated as a drug, until September 2025, when the agency reversed that position. It's legal to sell as a supplement again; as with any supplement, that says nothing about the quality of a given product.
• Nicotinamide (NAM) — cheap and effective at raising NAD+, but at high doses it inhibits sirtuins, which is somewhat self-defeating.
• Nicotinic acid (niacin) — effective, and causes flushing at meaningful doses.

What the human trials show

This is where the story becomes less tidy, and where most content on this topic quietly stops.

Precursors reliably raise NAD+. This part is settled. Multiple randomized, placebo-controlled trials show oral NR raises blood NAD+ in a dose-dependent way — commonly on the order of 40–60% at doses of 500–1000 mg daily. It's safe and well tolerated in trials running up to 12 weeks and beyond. If the question is "does it raise the number," the answer is yes.

Whether raising NAD+ produces clinical benefit is a separate question, and the answer so far is mixed at best.

In older adults, trials examining muscle function, insulin sensitivity, aerobic capacity, and body composition have largely returned null or marginal results. A frequently cited 21-day NR trial in older men raised NAD+ and reduced some circulating inflammatory cytokines, but did not improve muscle mitochondrial function or performance. Several careful studies have found no meaningful improvement in insulin sensitivity in overweight or insulin-resistant participants.

In neurological disease the signal is more interesting. The NADPARK study in Parkinson's disease found that NR raised brain NAD+ measured by magnetic resonance spectroscopy — an important demonstration that it reaches the target tissue — with mild clinical improvement in the subgroup showing an NAD+ increase. Larger follow-on trials have been conducted, and this remains one of the most promising directions.

NMN trials are smaller and generally shorter. Some report improved aerobic performance in amateur runners and modest improvements in walking distance and fatigue in middle-aged adults. Effect sizes are small and replication is limited.

Where that leaves things: these compounds raise NAD+, appear safe at studied doses, and have not yet demonstrated the functional or clinical benefits in humans that the animal work suggested. That's not a refutation. Aging trials are difficult — the outcomes worth measuring take years, the participants are heterogeneous, and short trials in already-healthy people are poorly designed to detect slow benefits. But it's the current state of evidence, and stating otherwise would be dishonest.

The gap between mouse and human

Some of the most striking findings come from rodents: restored mitochondrial function in aged muscle, improved endurance, better metabolic parameters, improvements in vascular function and neurological measures. Real results in real experiments.

Mice are also not small people. Laboratory mice live about two years, have far higher metabolic rates, carry different NAD+ metabolism kinetics, and are typically studied on a genetic background selected for uniformity in conditions nothing like human life. The history of aging research is substantially a history of interventions that extended rodent lifespan and did nothing measurable in humans.

That doesn't mean the mouse data is worthless — it means it generates hypotheses that human trials then have to earn. For NAD+ precursors, the human trials are still, on balance, in progress.

Injections, IV drips and nasal sprays

NAD+ delivered by IV infusion, subcutaneous injection or nasal spray has become a substantial commercial market, often at significant cost per session.

What's established: infusions do raise circulating NAD+ and its metabolites. Many people report subjective improvements in energy, mental clarity, and mood.

What isn't: there is very little controlled human trial evidence for injected or infused NAD+ in healthy adults. Almost none of the randomized data above used this route — it used oral precursors. Applying oral-precursor trial results to injectable NAD+ is not a valid inference.

Four things worth knowing before considering it:

Bioavailability is uncertain. Because extracellular NAD+ is degraded before cellular uptake, an infusion may function as an expensive and inefficient way of delivering nicotinamide. This is a real mechanistic question, not a quibble.

Infusions are physically unpleasant at speed. Rapid administration commonly causes chest tightness, nausea, flushing, abdominal cramping, and anxiety. This is why protocols run slowly, often over hours.

Nasal sprays have even less behind them. Intranasal NAD+ is marketed on the appeal of avoiding both needles and first-pass metabolism. The published human evidence for this route is thinner still — there is essentially no controlled trial data on intranasal NAD+ in healthy adults, and whether a molecule this large crosses the nasal mucosa in meaningful quantity is an open question rather than a settled one. It is more convenient than an infusion. That is not the same as being better supported.

Injectable, infused and intranasal NAD+ preparations are compounded products. They are not FDA-approved drugs. They have not been reviewed by the FDA for safety, efficacy, or manufacturing quality, and product quality varies with the compounding pharmacy. Anyone considering this should ask which pharmacy prepared it, whether that facility is state-licensed and inspected, and what testing it performs.

The placebo response in this space also deserves respect rather than dismissal. A quiet hour in a clinic, hydration, and the expectation of feeling better produce genuine subjective improvement. That's a real experience — it just isn't evidence of a cellular mechanism.

What actually raises NAD+ without a prescription

Underdiscussed, because nobody can charge for it:

Exercise. Physical activity upregulates NAMPT, the rate-limiting salvage-pathway enzyme, increasing your capacity to regenerate NAD+. Endurance training raises NAMPT expression in skeletal muscle substantially. This is the most robustly evidenced NAD+ intervention available, and it is free.

Caloric restriction and time-restricted eating. Both raise NAD+ in animal models, largely through the same salvage pathway.

Sleep. NAD+ metabolism is under circadian control, and NAMPT expression oscillates on a daily cycle. Circadian disruption degrades that rhythm.

Lowering inflammation. Because CD38 is inflammation-driven and CD38 consumes NAD+, reducing chronic inflammatory burden reduces the drain. This links back to visceral fat, sleep, alcohol, and the hs-CRP measurement worth tracking.

Avoiding excess DNA damage. PARP activation consumes NAD+. Sun protection and not smoking are, unglamorously, NAD+ interventions.

None of this is exciting. It is where the strongest evidence sits.

How to think about it

If you're weighing NAD+ therapy, a few ways to think about it:

It's a reasonable bet, not a proven intervention. The mechanism is real, the safety profile in trials looks acceptable, and the clinical benefit is unproven in humans. If you're comfortable spending on something with a plausible mechanism and incomplete evidence — knowing it may turn out to do nothing — that's a defensible adult decision. It should just be made with clear eyes.

Oral precursors have the actual human data. NR in particular has the most published randomized evidence. It's also far less expensive than infusion therapy.

Do the free things first. If you aren't training regularly, sleeping adequately, and managing inflammatory load, you're spending money to nudge a system you're actively depleting through other channels.

Measure something. If you try it, define in advance what would count as a benefit and track it — sleep quality, training performance, hs-CRP, subjective energy on a consistent scale. "I think I feel better" three months in, with nothing recorded at baseline, is not information you can act on.

Ask what you're being given. Compounded product, source pharmacy, dose, route. A program that can't answer those crisply hasn't earned your money.

The bottom line

NAD+ biology is one of the more mechanistically compelling threads in aging research. The decline is real. The enzymes that depend on it govern processes that plainly matter. Precursors demonstrably raise levels and appear safe.

What hasn't been shown is that raising NAD+ in a healthy adult produces meaningful functional benefit. It might. Trials are running. Anyone telling you the question is settled is selling something.

The parts of your reserve that are established — cardiorespiratory fitness, lean mass, metabolic health, arterial health — are still the ones with the strongest evidence and the highest return. Build those first. Treat NAD+ as an interesting adjunct with an open verdict, not a foundation.

---

Frequently asked questions

NR or NMN? NR has substantially more published human trial data. NMN is one step closer in the pathway, which is theoretically appealing but not demonstrated to matter clinically. NMN's US supplement status, disputed by the FDA from 2022, was restored in September 2025.

Do IV drips, injections or nasal sprays work better than pills? Unknown. Infusions raise circulating NAD+, but essentially all of the randomized human evidence used oral precursors, and mechanistic questions about cellular uptake remain unresolved — more so for the intranasal route, which has the least data of any of them. The cost difference is large.

How long until I feel something? Blood NAD+ rises within days to a couple of weeks on oral precursors. Whether you feel anything is a separate question — many trial participants on active drug felt nothing distinguishable from placebo.

Is it safe? Oral NR and NMN have been well tolerated in trials up to a year at studied doses. Long-term safety over many years is not established, and there is a theoretical concern about NAD+ availability in the presence of existing malignancy, since cancer cells also use NAD+. Discuss with a clinician if that applies to you.

Does it reverse aging? No human study has shown that. It's a research area with an unresolved verdict.